Hillevax Company Overview
About Hillevax
Hillevax (NASDAQ:HLVX) specializes in developing innovative solutions in the healthcare sector, focusing on vaccines and therapeutic agents aimed at addressing some of the most challenging diseases. It is actively involved in groundbreaking research, leading to the development of preventive and treatment options that promise to transform patient care worldwide. Through its commitment to excellence, Hillevax aims to significantly contribute to public health by advancing its portfolio of candidate vaccines into later stages of clinical trials, ensuring safety and efficacy for widespread use. Equipped with a state-of-the-art research facility and a team of dedicated scientists, Hillevax's projects are geared towards combating infectious diseases, aiming for a healthier future for all.
Snapshot
Operations
Products and/or services of Hillevax
- HIL-214, a next-generation norovirus vaccine aimed at providing robust protection against norovirus gastroenteritis.
- Preclinical development of a pipeline of vaccines targeting various infectious diseases beyond norovirus.
- Advanced research in novel adjuvant systems to enhance vaccine efficacy and duration of protection.
- Collaborations with leading global health organizations to accelerate vaccine development and access.
- Investment in cutting-edge manufacturing technologies to ensure scalable and efficient vaccine production.
- Engagement in community education and outreach programs to raise awareness about vaccine-preventable diseases.
Hillevax executive team
- Dr. Robert M. Hershberg M.D., Ph.D.Co-Founder, President, CEO & Chairman of the Board
- Dr. Aditya Kohli Ph.D.Co-Founder & Director
- Mr. Shane A. MaltbieCFO & Treasurer
- Dr. Anju Chatterji Ph.D.Chief Technology Officer
- Mr. Paul S. Bavier J.D.General Counsel, Secretary & Chief Administrative Officer